Eur J Pharmacol: Difference between revisions
From Bioblast
(Created page with "{{Journal |Title=Eur. J. Pharmacol. }}") Β |
No edit summary Β |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{Journal | {{Journal | ||
|Title= | |Title=[http://www.journals.elsevier.com/european-journal-of-pharmacology/ The European Journal of Pharmacology] | ||
}} | }} | ||
Latest revision as of 17:49, 22 March 2017
| Journal title and website | The European Journal of Pharmacology |
|---|
Publications
| Reference | Published | View | |
|---|---|---|---|
| Aya 2022 Eur J Pharmacol | Shiraki A, Oyama J, Shimizu T, Nakajima T, Yokota T, Node K (2022) Empagliflozin improves cardiac mitochondrial function and survival through energy regulation in a murine model of heart failure. Eur J Pharmacol 931: 175194. | 2022 | https://pubmed.ncbi.nlm.nih.gov/35987253/ |
| Brodnanova 2021 Eur J Pharmacol | Brodnanova M, Hatokova Z, Evinova A, Cibulka M, Racay P (2021) Differential impact of imipramine on thapsigargin- and tunicamycin-induced endoplasmic reticulum stress and mitochondrial dysfunction in neuroblastoma SH-SY5Y cells. Eur J Pharmacol 902:174073. | 2021 | PMID: 33798597 Open Access |
| Abu Bakar 2020 Eur J Pharmacol | Abu Bakar MH, Shariff KA, Tan JS, Lee LK (2020) Celastrol attenuates inflammatory responses in adipose tissues and improves skeletal muscle mitochondrial functions in high fat diet-induced obese rats via upregulation of AMPK/SIRT1 signaling pathways. Eur J Pharmacol 883:173371. | 2020 | PMID: 32712089 |
| Nambu 2019 Eur J Pharmacol | Nambu H, Takada S, Fukushima A, Matsumoto J, Kakutani N, Maekawa S, Shirakawa R, Nakano I, Furihata T, Katayama T, Yamanashi K, Obata Y, Saito A, Yokota T, Kinugawa S (2019) Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure. Eur J Pharmacol 866:172810. | 2019 | PMID: 31738936 Open Access |
| Bukowska 2019 Eur J Pharmacol | Bukowska A, Schild L, Bornfleth P, Peter D, Wiese-Rischke C, Gardemann A, Isermann B, Walles T, Goette A (2019) Activated clotting factor X mediates mitochondrial alterations and inflammatory responses via protease-activated receptor signaling in alveolar epithelial cells. Eur J Pharmacol 869:172875. | 2019 | PMID: 31877279 Open Access |
| Lukasiak 2016 Eur J Pharmacol | Εukasiak A, Skup A, Chlopicki S, Εomnicka M, Kaczara P, Proniewski B, Szewczyk A, Wrzosek A (2016) SERCA, complex I of the respiratory chain and ATP-synthase inhibition are involved in pleiotropic effects of NS1619 on endothelial cells. Eur J Pharmacol 786:137-47. | 2016 | PMID: 27262382 |
| Hansson 2015 Eur J Pharmacol | Hansson MJ, Llwyd O, Morin D, de Paulis D, Arnoux T, GouarnΓ© C, Koul S, Engblom H, Bordet T, Tissier R, Arheden H, Erlinge D, Halestrap AP, Berdeaux A, Pruss RM, Schaller S (2015) Differences in the profile of protection afforded by TRO40303 and mild hypothermia in models of cardiac ischemia/reperfusion injury. Eur J Pharmacol 760:7-19. | 2015 | PMID: 25895640 |
| Nowak 2010 Eur J Pharmacol | Nowak R, Wrzosek A, Lukasiak A, Rutkowska M, Adamus J, Gebicki J, Dolowy K, Szewczyk A, Tarasiuk J (2010) Effect of selected NAD+ analogues on mitochondria activity and proliferation of endothelial EA.hy926 cells. Eur J Pharmacol 640:102-11. | 2010 | PMID: 20447392 |
| Wrzosek 2009 Eur J Pharmacol | Wrzosek A, Lukasiak A, Gwozdz P, Malinska D, Kozlovski VI, Szewczyk A, Chlopicki S, Dolowy K (2009) Large-conductance K+ channel opener CGS7184 as a regulator of endothelial cell function. Eur J Pharmacol 602:105-11. | 2009 | PMID: 19028489 |
| Franciso 2007 Eur J Pharmacol | Franciso R, Perez-Tomas R, Gimenez-Bonafe P, Soto-Cerrato V, Gimenez-Xavier P, Santiago A (2007) Mechanisms of prodigiosin cytotoxicity in human neuroblastoma cell lines. Eur J Pharmacol 572:111-9. | 2007 | PMID: 17678643 |
